| |
Newsroom /
Health and Fitness
/
Healthcare
/
Atopic Dermatitis – Drug Pipeline Analysis and Market Forecasts to 2016
Atopic Dermatitis – Drug Pipeline Analysis and Market Forecasts to 2016
Increasing Competition from Generics Manufacturers Pose a Threat to the Growth of the Market
Hyderabad,
AP,
India
(prbd.net)
05/02/2010
"Atopic Dermatitis, Drug Pipeline, Market Analysis, therapeutics,"
The global atopic dermatitis market is heavily fragmented with numerous generic products at relatively low prices. The patent expiry of marketed products such as Protopic and Elidel by 2012 – 2015 would allow the further entry of generic products at cheaper prices reducing market growth as well as the market size.
GlobalData has estimated the global atopic dermatitis therapeutics market to be valued at $643m in 2009. It is expected to grow to $810m at a Compound Annual Growth Rate (CAGR) of 3.4% by 2016. This growth is primarily attributed to an increase in competition among existing products and the presence of a strong pipeline with more emerging therapies. Globally, the US remains the largest market for atopic dermatitis therapeutics, and was valued at $402m in 2009. It is forecast to grow at a CAGR of 3.8% over the next seven years to reach $582m by 2016. However, with most of the demand expected to come from the developed economies, the center of global atopic dermatitis therapeutics market activity is potentially due for a paradigm shift.
In the year 2009, there were approximately 35 million cases of Atopic dermatitis reported within the 7 geographies (the US, the UK, Germany, France, Spain, Italy and Japan). This equated to a prevalence of approximately 4.5%. GlobalData estimates that the number of Atopic dermatitis patients is forecast to increase to about 40 million by 2016, representing an increase in prevalence by approximately 1%. Some of the factors associated with an increased risk of atopic dermatitis include small family size, higher socioeconomic and educational levels regardless of ethnicity, movement from rural to urban environment, and increased use of antibiotics. Research has indicated that there is a predominance of type-2 helper T cells (Th2) in atopic dermatitis. Higher number of cases would involve the increased uptake of therapeutics, thereby increasing the growth of the market.
GlobalData, the industry analysis specialist, has released its latest research “Atopic Dermatitis - Drug Pipeline Analysis and Market Forecasts to 2016”. It provides key data, information and analysis on the global Atopic dematitis therapeutics market. The report provides a comprehensive overview of annualized market data from 2001 to 2009, and forecasts for the next seven years to 2016. The report covers the market landscape, market drivers and restraints, and an in-depth pipeline analysis. The current competitive landscape is analyzed along with the prevailing unmet need or commercial opportunities of the market. The pipeline analysis covers molecules across all phases of clinical development and gives an overview of the developing trends among pipeline molecules, as well as, an insight into the most promising pipeline drugs, supplemented with key company profiles. By considering the current competition in the market and the prospects of the pipeline molecules, the resulting implications for future market competition is also outlined.
Or visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|